Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. Research shows that the drug activates the cannabinoid ...

NDAQ:AVXL) Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of ...

Aging involves gradual functional decline across various biological systems, including impaired cellular mechanisms such as ...

Company to Present Breakthrough Research Approach for a New Generation of Neurodegenerative Therapeutics GAINESVILLE, Fla., ...

Scientists have developed an advanced multi-organ model to deepen the understanding of the gut-brain connection in ...

Lisa Volenec was diagnosed with early-onset Parkinson's a decade ago. In recent months, she has realized the power of her own ...

An audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. A replay of the session will be available later that day. About Anavex Life Sciences Corp.

Gain Therapeutics' GT-02287 shows promise in treating Parkinson's disease, with positive results and potential for market ...

IRX-4204 is under clinical development by Io Therapeutics and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition ...

providing a means to assess motor coordination in animal models of Parkinson's disease (PD). In the early stages of PD, rodents show a slight increase in traversal time. As the disease progresses to ...